1. Home
  2. ALX vs ABCL Comparison

ALX vs ABCL Comparison

Compare ALX & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexander's Inc.

ALX

Alexander's Inc.

HOLD

Current Price

$230.57

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$3.51

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALX
ABCL
Founded
1928
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
ALX
ABCL
Price
$230.57
$3.51
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.75
AVG Volume (30 Days)
41.7K
2.2M
Earning Date
05-04-2026
05-11-2026
Dividend Yield
7.91%
N/A
EPS Growth
N/A
10.91
EPS
5.50
N/A
Revenue
$213,183,000.00
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$25.44
P/E Ratio
$41.38
N/A
Revenue Growth
N/A
160.56
52 Week Low
$189.05
$1.89
52 Week High
$260.84
$6.52

Technical Indicators

Market Signals
Indicator
ALX
ABCL
Relative Strength Index (RSI) 39.88 52.21
Support Level $229.26 $3.37
Resistance Level $235.65 $3.57
Average True Range (ATR) 6.89 0.15
MACD -1.52 0.01
Stochastic Oscillator 22.11 59.90

Price Performance

Historical Comparison
ALX
ABCL

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: